Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05849064
Other study ID # STUDY23020055
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 7, 2023
Est. completion date December 2024

Study information

Verified date September 2023
Source University of Pittsburgh
Contact Anthony Kontos, PhD
Phone 412-432-3725
Email akontos@pitt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to conduct the first randomized control trial for targeted treatments for concussion in adults 50 years or older. Participants will be enrolled at their first concussion clinical visit (V1) and their second study visit will occur after (up to 7 days) or concurrently with the participant's second concussion clinical visit, typically (but not limited to) between 21-31 days from V1.


Description:

Although concussion is a common occurrence in older adults, we know little about the injury in this at-risk population. Certain management tools that might be appropriate for adolescent and young adult populations may not be appropriate for use in older adults who may have sensory, cognitive, and neuro-motor limitations. This study will help to develop initial evidence for targeted treatments for concussion in older adults. The study will utilize a two group design with permuted block random assignment to intervention and usual care/control groups. All participants will complete the following assessments at their initial and follow-up visit appointments: cognitive screening (learning, memory, language, executive functioning), concussion and mood symptom questionnaires, and neuro-motor screening. The primary outcomes for this study will be total symptom severity score (i.e., symptom burden) on the Concussion Clinical Profiles Screening (CP Screen) and Patient Global Impression of Change (PGIC). Secondary outcomes will include: Short Falls Efficacy Scale (SFES), Dizziness Handicap Inventory (DHI), Patient Health Questionnaire-9 (PHQ-9), Patient Health Questionnaire-15 (PHQ-15), Generalized Anxiety Disorder - 7 (GAD-7), Posttraumatic Stress Disorder Checklist (PCL-5), Pittsburgh Sleep Quality Index (PSQI), Neuro-Quality of Life (QOL) v2.0 - Cognition Function (Short version), Headache Impact Test (HIT-6), ID Migraine, Neck Disability Index (NDI), Vestibular Ocular Motor Screen (VOMS), Timed-Up-and-Go (TUG), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). All outcomes will be treated as continuous.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years to 99 Years
Eligibility Inclusion Criteria: - 50 years of age or older - Diagnosed concussion within the last 4 days - 12 months - Must be recruited at their initial concussion appointment - Ability to read/write to complete study assessments/testing Exclusion Criteria: - Diagnosed neurological disorder (stroke, dementia, epilepsy) - Diagnosed major psychiatric disorders other than depression/anxiety (e.g., schizophrenia) - Diagnosed with moderate to severe brain injury or past brain surgery/malformations

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral Control
Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
Targeted Intervention
Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.

Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concussion Clinical Profiles Screening (CP Screen) The CP Screen is a 29 item self-report, clinical profiles based symptom inventory that measures five concussion clinical profiles: 1) anxiety/mood, 2)cognitive/fatigue, 3) migraine, 4) ocular, 5) vestibular; and two modifying factors sleep and cervical. Participants indicate on a scale of 0 (none) to 3 (severe) the level of symptom severity for each item. The CP screen yields an average factor and modifier scores, with higher scores indicative of worse symptom severity, score range is 0-87. Visit 1 (Baseline)
Primary Concussion Clinical Profiles Screening (CP Screen) The CP Screen is a 29 item self-report, clinical profiles based symptom inventory that measures five concussion clinical profiles: 1) anxiety/mood, 2)cognitive/fatigue, 3) migraine, 4) ocular, 5) vestibular; and two modifying factors sleep and cervical. Participants indicate on a scale of 0 (none) to 3 (severe) the level of symptom severity for each item. The CP screen yields an average factor and modifier scores, with higher scores indicative of worse symptom severity, score range is 0-87. At study completion, an average of 30 days after Visit 1
Secondary Vestibular/Ocular Motor Screening (VOMS) The VOMS assesses impairment via patient report symptom provocation following each of 5 test components (smooth pursuits, horizontal/vertical saccades, convergence, horizontal and vertical vestibular ocular reflex (VOR) and visual motor sensitivity (VMS). Patients verbally rate changes in headache, dizziness, nausea, and fogginess after each test, as well as report their baseline symptoms. Symptoms in each area are rated on scale 0 (none) to 10 (severe). Scores on any VOMS item of 2+ reflects a positive screening cut-off for vestibular and/or ocular motor impairment. Visit 1 (Baseline)
Secondary Vestibular/Ocular Motor Screening (VOMS) The VOMS assesses impairment via patient report symptom provocation following each of 5 test components (smooth pursuits, horizontal/vertical saccades, convergence, horizontal and vertical vestibular ocular reflex (VOR) and visual motor sensitivity (VMS). Patients verbally rate changes in headache, dizziness, nausea, and fogginess after each test, as well as report their baseline symptoms. Symptoms in each area are rated on scale 0 (none) to 10 (severe). Scores on any VOMS item of 2+ reflects a positive screening cut-off for vestibular and/or ocular motor impairment. At study completion, an average of 30 days after Visit 1
Secondary Short Falls Efficacy Scale (SFES) The SFES is a 7 item survey that measures a subject's fear and concerns about falling during normal daily life activities. Question responses are scaled from 1-4, with higher scores indicating more concern for falls. (Low concern = 7-8; Moderate concern = 9-13; High concern = 14-28). Visit 1 (Baseline)
Secondary Short Falls Efficacy Scale (SFES) The SFES is a 7 item survey that measures a subject's fear and concerns about falling during normal daily life activities. Question responses are scaled from 1-4, with higher scores indicating more concern for falls. (Low concern = 7-8; Moderate concern = 9-13; High concern = 14-28). At study completion, an average of 30 days after Visit 1
Secondary Patient Health Questionnaire-9 (PHQ-9) The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression. Total score ranges from 1-27, with higher scores indicating higher level of depression. Scale is 0-4 (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day). Visit 1 (Baseline)
Secondary Patient Health Questionnaire-9 (PHQ-9) The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression. The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression. Total score ranges from 1-27, with higher scores indicating higher level of depression. Scale is 0-4 (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day). At study completion, an average of 30 days after Visit 1
Secondary Patient Health Questionnaire-15 (PHQ-15) The PHQ-15 comprises 15 somatic symptoms that are scored from 0 ("not bothered at all") to 2 ("bothered a lot"). Higher scores are indicative of higher levels of depression (Minimal =0-4; Low = 5-9; Medium = 10-14; High = 15=30). Visit 1 (Baseline)
Secondary Patient Health Questionnaire-15 (PHQ-15) The PHQ-15 comprises 15 somatic symptoms that are scored from 0 ("not bothered at all") to 2 ("bothered a lot"). Higher scores are indicative of higher levels of depression (Minimal =0-4; Low = 5-9; Medium = 10-14; High = 15=30). At study completion, an average of 30 days after Visit 1
Secondary General Anxiety Disorder-7 (GAD-7) The GAD-7 is a seven item self-reported questionnaire that measures severity of symptoms regarding anxiety. Responses are 0 = not at all, 1 = several days, 2= more than half the days, and 3 = nearly every day. Higher scores are indicative of higher anxiety (0-4 = minimal anxiety, 5-9= mild anxiety, 10-14 =moderate anxiety, 15-21 = severe anxiety. Visit 1 (Baseline)
Secondary General Anxiety Disorder-7 (GAD-7) The GAD-7 is a seven item self-reported questionnaire that measures severity of symptoms regarding anxiety. Responses are 0 = not at all, 1 = several days, 2= more than half the days, and 3 = nearly every day. Higher scores are indicative of higher anxiety (0-4 = minimal anxiety, 5-9= mild anxiety, 10-14 =moderate anxiety, 15-21 = severe anxiety. At study completion, an average of 30 days after Visit 1
Secondary PCL-5 The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Responses are on a 5 point likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely). Overall score is total sum of 20 items with higher scores indicating higher level of PTSD (Range 0-80) Visit 1 (Baseline)
Secondary PCL-5 The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Responses are on a 5 point likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely). Overall score is total sum of 20 items with higher scores indicating higher level of PTSD (Range 0-80). At study completion, an average of 30 days after Visit 1
Secondary Neuro-QOL (Cognitive Function Scale - short form) The cognitive function measures perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning). The short form contains 8 items, scored 0-5 (5=never, 4=rarely/once, 3=sometimes/2-3 times, 2=often/once a day, 1=very often/several times per day. Total scores range from 0-40. Higher scores indicate better self-reported cognitive function. Visit 1 (Baseline)
Secondary Neuro-QOL (Cognitive Function Scale - short form) The cognitive function measures perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning). The short form contains 8 items, scored 0-5 (5=never, 4=rarely/once, 3=sometimes/2-3 times, 2=often/once a day, 1=very often/several times per day. Total scores range from 0-40. Higher scores indicate better self-reported cognitive function. At study completion, an average of 30 days after Visit 1
Secondary Dizziness Handicap Inventory (DHI) The DHI is a 25 item self-reported measure that examines dizziness-related handicap. The assessment has 3 domains (functional, emotional, and physical). Participants self-report the level dizziness has impacted their abilities in the 3 domains with each domain having 9 questions (questions are answered No (0)/Sometimes(2)/Yes(4)) Item scores are summed. There is a maximum score of 100 (28 points for physical, 36 points for emotional and 36 points for functional). Minimum score is 0. Visit 1 (Baseline)
Secondary Dizziness Handicap Inventory (DHI) The DHI is a 25 item self-reported measure that examines dizziness-related handicap. The assessment has 3 domains (functional, emotional, and physical). Participants self-report the level dizziness has impacted their abilities in the 3 domains with each domain having 9 questions (questions are answered No (0)/Sometimes(2)/Yes(4)) Item scores are summed. There is a maximum score of 100 (28 points for physical, 36 points for emotional and 36 points for functional). Minimum score is 0. At study completion, an average of 30 days after Visit 1
Secondary Headache Impact Test-6 (HIT-6) The HIT-6 is comprised of 6 self-report items that assess frequency, severity and limitations of daily activities, fatigue, irritability, and concentration related to headaches. Items score from 6 to 13, with higher scores indicating worse severity. Scores = never = 6pts, rarely = 8 pts, sometimes = 10pts, very often = 11 pts, always = 13 points. Score range 36-78. Visit 1 (Baseline)
Secondary Headache Impact Test-6 (HIT-6) The HIT-6 is comprised of 6 self-report items that assess frequency, severity and limitations of daily activities, fatigue, irritability, and concentration related to headaches. Items score from 6 to 13, with higher scores indicating worse severity. Scores = never = 6pts, rarely = 8 pts, sometimes = 10pts, very often = 11 pts, always = 13 points. Score range 36-78. At study completion, an average of 30 days after Visit 1
Secondary ID Migraine The ID Migraine will be used to screen for headache symptoms. It is a 3 item screening tool designed to assess presence (yes/no) of symptoms related to headache/migraine pain. Scores range from 0-3 with clinical cut-off of 2+ indicating presence of migraines. Visit 1 (Baseline)
Secondary ID Migraine The ID Migraine will be used to screen for headache symptoms. It is a 3 item screening tool designed to assess presence (yes/no) of symptoms related to headache/migraine pain. Scores range from 0-3 with clinical cut-off of 2+ indicating presence of migraines. At study completion, an average of 30 days after Visit 1
Secondary Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) RBANS provides a brief, individually administered battery to measure cognitive decline or improvement across 5 domains (Immediate memory, visuospatial/constructional, language, attention, and delayed memory. There are total scores and indices scores, which are different depending on age and gender. Higher scores indicate better performance for all 5 domains. (<69=extremely low, 70-79=borderline, 80-89-low average, 90-109=average, 110-119=high average, 120-129=superior, 130 and higher = very superior). Visit 1 (Baseline)
Secondary Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) RBANS provides a brief, individually administered battery to measure cognitive decline or improvement across 5 domains (Immediate memory, visuospatial/constructional, language, attention, and delayed memory. There are total scores and indices scores, which are different depending on age and gender. Higher scores indicate better performance for all 5 domains. (<69=extremely low, 70-79=borderline, 80-89-low average, 90-109=average, 110-119=high average, 120-129=superior, 130 and higher = very superior). At study completion, an average of 30 days after Visit 1
Secondary Neck Disability Index Neck pain scale, each item scores 0-5 with range 0-50. Overall score out of 50 is multiplied by 100 to get a percentage. 0-20% = minimal disability, 20-40% is moderate disability, 40-60% severe disability, 60-80% = crippled, 80-100% =participants are either bed-bound or exaggerating symptoms. Visit 1 (Baseline)
Secondary Neck Disability Index Neck pain scale, each item scores 0-5 with range 0-50. Overall score out of 50 is multiplied by 100 to get a percentage. 0-20% = minimal disability, 20-40% is moderate disability, 40-60% severe disability, 60-80% = crippled, 80-100% =participants are either bed-bound or exaggerating symptoms. At study completion, an average of 30 days after Visit 1
Secondary Pittsburgh Sleep Quality Index (PSQI) The PSQI assesses sleep quality. It is an 19 item self-reported measure that is comprised of seven component scores: 1) subjective sleep quality, 2) sleep latency, 3) sleep duration, 4) sleep efficiency, 5) sleep disturbances, 6) sleep medication usage, and 7) daytime dysfunction. Each item is scored 0-3 (0 = very good, 1 = fairly good, 2= fairly bad, 3=very bad). Higher scores indicate more sleep dysfunction. Score range is 0-21. Visit 1 (Baseline)
Secondary Pittsburgh Sleep Quality Index (PSQI) The PSQI assesses sleep quality. It is an 19 item self-reported measure that is comprised of seven component scores: 1) subjective sleep quality, 2) sleep latency, 3) sleep duration, 4) sleep efficiency, 5) sleep disturbances, 6) sleep medication usage, and 7) daytime dysfunction. Each item is scored 0-3 (0 = very good, 1 = fairly good, 2= fairly bad, 3=very bad). Higher scores indicate more sleep dysfunction. Score range is 0-21. At study completion, an average of 30 days after Visit 1
Secondary Timed-Up-and-Go Walking balance test, distance of 3 meters (10 feet). Participants are timed. Participants are seated in a chair, instructed to get up, walk 3 meters (marked on floor or by cone), round the cone, return to the chair and sit back down. Participants will repeat this 3 times, and we will use the average time. < 10 second = normal, <20 seconds, good mobility, <30 second, problems/may require aid. Higher scores indicating more problems with mobility. Visit 1 (Baseline)
Secondary Timed-Up-and-Go Walking balance test, distance of 3 meters (10 feet). Participants are timed. Participants are seated in a chair, instructed to get up, walk 3 meters (marked on floor or by cone), round the cone, return to the chair and sit back down. Participants will repeat this 3 times, and we will use the average time. < 10 second = normal, <20 seconds, good mobility, <30 second, problems/may require aid. Higher scores indicating more problems with mobility. At study completion, an average of 30 days after Visit 1
Secondary Patient's Global Impression of Change (PGIC) PGIC is a self-reported assessment of change. Participants rate their impression of how much better they feel on a 7 point likert scale. It is a 1 item survey, with higher scores representing no change and associated with feeling worse. (Responses 1=much improved, 2=minimally improved, 3=no change, 4=minimally worse, 5=much worse, 6=very much worse). Daily between Visit 1 and study completion, an average of 30 days
Secondary Percent Back to Normal Subject rates on a scale from 0% to 100% how much they feel like they are back to normal (before injury) Daily between Visit 1 and study completion, an average of 30 days
See also
  Status Clinical Trial Phase
Terminated NCT04586179 - A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion N/A
Not yet recruiting NCT05943561 - Biomarkers in Concussion
Completed NCT02721537 - Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes N/A
Completed NCT03236389 - Brain Dynamics in Response to Jugular Vein Compression N/A
Completed NCT01832714 - Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event
Completed NCT04560400 - Reverse King-Devick Test and History of Multiple Concussions N/A
Completed NCT03678077 - Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
Recruiting NCT05262361 - Persistent Post-Concussion Symptoms With Convergence Insufficiency N/A
Recruiting NCT05105802 - Mindfulness-Based Intervention for Mild Traumatic Brain Injury N/A
Terminated NCT03123822 - Spectacles Lens in Concussed Kids N/A
Completed NCT04641832 - The Combined Effect of Chronic Cannabis Use and Subconcussive Head Impacts on Brain Health N/A
Completed NCT04074486 - Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
Withdrawn NCT04578743 - Exercise as Concussion Therapy Trial- 2 Phase 2
Completed NCT03170856 - The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion N/A
Completed NCT03671083 - Validation of Brain Function Assessment Algorithm for mTBI/Concussion
Completed NCT05069948 - Delivery of Digital Cognitive Behavioural Therapy Following Concussion N/A
Recruiting NCT03889483 - Neurophysiological Measurements Using the NeuroCatchâ„¢ Platform in Pediatric Concussion N/A
Withdrawn NCT02959294 - Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries Early Phase 1
Recruiting NCT06093295 - Non-invasive Brain Stimulation and Injury Risk Biomechanics N/A
Completed NCT02280304 - Meditation in Veterans With PTSD and Mild TBI N/A